UK university uses graphene to develop lung cancer detection device
Category: #health  By Mateen Dalal  Date: 2019-02-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

UK university uses graphene to develop lung cancer detection device

The new device possesses the potential to detect specific lung cancer markers at the earliest stage possible.

In what may seem to a pathbreaking revolutionary finding in global healthcare, scientists at the University of Exeter, UK, have reportedly developed a graphene-based biosensor. If sources are to be believed, the biosensor may be capable of sniffing out any evidence of lung cancer merely from the persons breath, thereby paving the way ahead to develop cost-effective, early diagnosis systems.

The new technique, brainstormed by researchers at Exeter, has been touted to generate a highly sensitive graphene biosensor equipped with the capability to identify molecules of the most common lung cancer biomarkers. As reported by Times Now, the new biosensor design is likely to revolutionize the currently existing e-nose devices, which identify specific components of a specific vapor mixture – say for instance, a patient’s breath, and analyze its chemical makeup for cause detection.

Sources familiar with the knowledge of the matter claim that the low-cost device depicts ample potential to identify particular lung cancer markers at the earliest stage plausible. Apart from being cost-efficient, the device has also been speculated to prove highly advantageous for medical service providers worldwide.

Ben Hogan, postgraduate researcher, University of Exeter, has been reported to state that the newly developed biosensors provides substantial testimony to prove that graphene is equipped with enough potential to be deployed as an electrode for e-nose devices. This is the first time when the university has depicted that with the appropriate patterning, graphene can be effectively used as a selective, sensitive detector for biomarkers, elaborated Hogan.

The research team claims that using multi-layered graphene, the existing e-nose devices that basically combine electronic sensors along with mechanisms for recognizing patterns such as neural networks, will be capable of transforming breath diagnostic techniques. This could essentially be the debut step forward to creating novel, enhanced, and low-cost e-nose devices that may most plausibly provide the earliest lung-cancer diagnosis.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutic...

Ikea invests in India’s one-stop interior design platform Livspace
Ikea invests in India’s one-stop interior design platform Livspace
By Mateen Dalal

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in India’s ...

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
By Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailabil...